Medicare sticks to coverage limits on Biogen's Aduhelm - Fierce Pharma

UPDATE: Bluebird bio's $2.8M gene therapy Zynteglo wins FDA backing. Will its US launch take flight? Aug 17, 2022 01:55pm.
https://www.google.com/url?rct=j&sa=t&url=https://www.fiercepharma.com/pharma/cms-sticks-its-guns-will-limit-coverage-biogens-aduhelm-clinical-trials&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AOvVaw0vpDx70KplNmadJvPIlpRv